 
|
Advocacy
Please consider supporting
important pending legislation
We'd like to draw
viewers attention to U.S. Senate ACCESS Act (S.1956) that will benefit
those (together with their physicians) who wish to have access
to the greatest possible array of treatment options, especially
drugs in development. For more information, click here.
August 19, 2005
- The Lorenzen Cancer Foundation
has joined the public interest law firm Washington Legal Foundation,
the Abigail Alliance and the Lung Cancer Alliance in presenting
comments to the Centers for Medicare & Medicaid Services
concerning the labeling of Iressa (Gefitinib) under Part D. For
a text of the written presented Comments, click here.
-
-
- July
25, 2005
- The Lorenzen Cancer Foundation
has joined the public interest law firm Washington Legal Foundation,
the Abigail Alliance and the Lung Cancer Alliance in presenting
comments to the Food and Drug Administration concerning the labeling
of Iressa (Gefitinib). For a text of the written presented Comments,
click here.
-
-
- April
20, 2005
- The Lorenzen Cancer Foundation
has joined the public interest law firm Washington Legal Foundation
and the Abigail Alliance in presenting comments to the Food and
Drug Administration concerning Public Citizen, Inc. Petition
for withdrawal of Iressa (Gefitinib). For a text of the written
presented Comments, click here.
-
-
- March
21, 2005
- The Lorenzen Cancer Foundation
has joined the public interest law firm Washington Legal Foundation
and the Abigail Alliance in presenting comments to the Drug Enforcement
Administration, U.S. Department of Justice concerning dispensing
of pain medications. For a text of the written presented Comments,
click here.
-
-
- August 20, 2004
- The Lorenzen Cancer Foundation
has joined the public interest law firm Washington Legal Foundation
and the Abigail Alliance in presenting comments to the the cross-agency
task force as gathered by the U.S. Department Health and Human
Services concerning stimulating Innovation (and reducing barriers)
in medical technologies. For a text of the written presented
Comments, click here.
-
-
- June
25, 2004
- The Lorenzen Cancer Foundation
has joined the public interest law firm Washington Legal Foundation
in presenting a statement to Medicare officials voicing support
for the Section 641 demonstration project and expressing concerns
regarding CMS's proposed restrictions limiting coverage of the
drug benefit to exclude off-label uses of FDA-approved drug or
biological therapies. For a text of the written presented Statement
and the Press Release, click here.
-
-
- February
10, 2004
- The Lorenzen Cancer Foundation
has joined the Washington Legal Foundation in Urging Medicare
Officials to Cover Cancer Drugs. For a text of the written presented
Comments and the Press Release, click here.
Pancreatic cancer is the most
virulent of the major cancers; it is also the least funded
of the major cancers. A combination with terrible consequences.
Cancer is the second most common
cause of death in the developed world, behind cardiovascular
disease. Pancreatic cancer is the fourth most common cause of
cancer mortality (behind lung cancer, colorectal cancer and breast
cancer). It is the third most common cause of cancer death in
men and the fifth in women.
250 people in North America and
Europe will die TODAY from pancreatic cancer. (90,000 deaths
per year).
The U.S. National Cancer Institute
funds pancreatic cancer research at shockingly low levels (year
2005-07 figures). Pancreatic cancer research receives (per mortality):
 15%
of the funding of breast cancer (but causes 82% of the mortality)
 17% of the funding of prostate
cancer (but causes more mortality)
41% of the funding of colorectal
cancer (but causes 63% of the mortality)
Pancreatica.org continues to
support legislative and other effort aimed at increasing the
funding support for pancreatic cancer treatment and research
at the U.S. Federal level and at the States level.
Please get involved. |
